|
Feb 24
|
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now
|
|
Feb 15
|
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 14
|
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
|
|
Feb 14
|
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...
|
|
Feb 14
|
Q4 2024 Blueprint Medicines Corp Earnings Call
|
|
Feb 13
|
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 13
|
Blueprint Medicines: Q4 Earnings Snapshot
|
|
Feb 13
|
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
|
|
Feb 11
|
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
|
|
Jul 29
|
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
|
|
Jul 25
|
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
|
|
May 21
|
Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
|
|
May 7
|
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
|
|
May 6
|
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
|
|
May 3
|
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
|
|
May 3
|
Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...
|
|
May 3
|
Q1 2024 Blueprint Medicines Corp Earnings Call
|
|
May 2
|
Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...
|
|
May 2
|
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
|